Search results

Evidence-based recommendations on atezolizumab (Tecentriq) for locally advanced or metastatic non-small-cell lung cancer after chemotherapy in adults.

Result type

Technology appraisal guidance

Published

16 May 2018

Evidence-based recommendations on guselkumab (Tremfya) for treating moderate to severe plaque psoriasis in adults.

Result type

Technology appraisal guidance

Published

13 June 2018

Evidence-based recommendations on midostaurin (Rydapt) for untreated FLT3-mutation-positive acute myeloid leukaemia in adults.

Result type

Technology appraisal guidance

Published

13 June 2018

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive Hodgkin lymphoma in adults.

Result type

Technology appraisal guidance

Published

13 June 2018

Evidence-based recommendations on tivozanib (Fotivda) for treating advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

21 March 2018

Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic (secondary) breast cancer in adults who have had only 1 course of chemotherapy.

Result type

Technology appraisal guidance

Published

28 March 2018

Evidence-based recommendations on cabozantinib (Cometriq) for treating medullary thyroid cancer in adults.

Result type

Technology appraisal guidance

Published

28 March 2018

Evidence-based recommendations on autologous chondrocyte implantation using chondrosphere (Spherox) for treating symptomatic articular cartilage defects of the knee in adults.

Result type

Technology appraisal guidance

Published

7 March 2018

Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults.

Result type

Technology appraisal guidance

Published

21 March 2018

Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C in adults.

Result type

Technology appraisal guidance

Published

21 February 2018

Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

Result type

Technology appraisal guidance

Last updated

2 July 2021

Evidence-based recommendations on rivaroxaban (Xarelto) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

Result type

Technology appraisal guidance

Last updated

2 July 2021

Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

Result type

Technology appraisal guidance

Last updated

2 July 2021

Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma in adults.

Result type

Technology appraisal guidance

Last updated

8 February 2021

Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

Result type

Technology appraisal guidance

Last updated

2 July 2021